Back to Search
Start Over
Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus
- Source :
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 13:2119-2127
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- Introduction To investigate effects of Sitagliptin on the enhancement of beta-cell function, reducing insulin resistance, serum glucagon like peptide-1 (GLP-1) concentrations and blood glucose in patients with type 2 diabetes mellitus (T2D) and suggest one of the underlying mechanisms on beta-cell function and insulin resistance. Patients and methods This was a cross-sectional and observational study in comparison to the control group. A study population of 44 newly diagnosed patients with T2D treated with Sitagliptin with a dose of 100 mg/day for 3 months was analyzed to compare 52 healthy participants. Indices for beta-cell function, peripheral insulin sensitivity, and insulin resistance were calculated with homeostasis model assessment 2 (HOMA2) calculator and compared. Serum GLP-1 concentrations were analyzed, and regression analysis was conducted to find the correlations between GLP-1 and beta-cell function and insulin resistance. Results Newly diagnosed patients with T2D witnessed a significant reduction in beta-cell function, serum GLP-1 concentrations at the time of diagnosis. After treatment with Sitagliptin 100 mg/day, they achieved significant improvements in beta-cell function, peripheral insulin sensitivity and insulin resistance. Serum GLP-1 concentrations were increased significantly to those levels in the control group and correlated with peripheral insulin sensitivity and insulin resistance in patients whose beta-cell functions improved. Conclusion Sitagliptin improved beta-cell function, insulin resistance and blood glucose in newly diagnosed patients with T2D. Meanwhile, Sitagliptin ameliorated serum GLP-1 concentrations, which contributed to the enhancement of beta-cell.
- Subjects :
- Pharmacology
medicine.medical_specialty
business.industry
Type 2 Diabetes Mellitus
030209 endocrinology & metabolism
Newly diagnosed
030204 cardiovascular system & hematology
medicine.disease
Glucagon
Peripheral
03 medical and health sciences
0302 clinical medicine
Endocrinology
Insulin resistance
Sitagliptin
Internal medicine
Internal Medicine
medicine
Population study
business
Homeostasis
medicine.drug
Subjects
Details
- ISSN :
- 11787007
- Volume :
- 13
- Database :
- OpenAIRE
- Journal :
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Accession number :
- edsair.doi...........97d3c7add5ea7850b5ff0d3046a8900d
- Full Text :
- https://doi.org/10.2147/dmso.s255071